Q-omics provides the consensus-scored SLC15A2 profile across patient tissues and cancer cell-line models. SLC15A2 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, SLC15A2 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, SLC15A2 RNA expression shows 18,539 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LUAD, KIRC, and UVM as cancer lineages where SLC15A2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC15A2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC15A2 survival associations across molecular data types. SLC15A2 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (11) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC15A2 RNA expression–survival associations across cancer types. High SLC15A2 expression shows unfavorable associations in STAD, but favorable associations in LUAD, SKCM, LGG, READ and HNSC. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for SLC15A2 RNA expression.
This table summarizes SLC15A2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC15A2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC15A2 shows lower tumor expression in KIRC, KICH, LUAD, KIRP, THCA and COAD. The KIRC box plot shows higher SLC15A2 RNA expression in normal versus tumor tissue (log2 FC = −3.082, t-test p < 0.001).
This table shows molecular features associated with SLC15A2 in patient tissues and cancer cell lines. In patient samples, SLC15A2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC15A2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Lymphoma.
